跳至主要内容
临床试验/NCT05549622
NCT05549622已完成不适用

Impact of a High-Soluble Fiber Diet on the Gut-Muscle Axis in Older Adults

Tufts University2 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2023年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
31
试验地点
2
主要终点
Chair stand test

研究概览

简要总结

Muscle health declines during aging. One factor that may impact muscle health is the community of bacteria that live in our intestines, but studies aimed at improving muscle health by targeting the gut in older adults are sparse. The primary goal of this study is to use a diet that is enriched in soluble fiber, which is exclusively utilized by gut bacteria to make substances that can impact muscle health, to improve muscle-related measures in older adults.

详细描述

During aging, skeletal muscle mass and physical function decrease, whereas levels of lipids and adipocytes increase within and between muscle cells, thereby worsening muscle composition. As a result of these age-related changes, older adults are at a higher risk for frailty, falls and fracture, disability and hospitalization, and all-cause mortality. Accordingly, elucidation of mechanisms that underlie muscle mass, muscle composition, and physical function, and interventions that positively affect these variables will be important for addressing the public health priority of an improved quality of life and healthy aging in older adults.

The gut microbiome and its metabolic products are involved in mechanisms that impact skeletal muscle mass, muscle composition, and physical function, which has been defined as the gut-muscle axis. For example, muscle mass and physical function are reduced in animals that do not have a microbiome (germ-free mice), and in antibiotic-treated mice, an intervention that reduces gut bacterial content. Investigating further, gut bacteria-derived metabolites affect muscle mass, muscle composition, and physical function in young and aged animals, including positive effects for the short-chain fatty acids (SCFAs) acetate, propionate, and butyrate, and negative effects for indoxyl sulfate (IS) and para-cresol sulfate (PCS). Similarly, phenol sulfate (PS) and phenylacetylglutamine (PAG) are gut microbiome-derived metabolites that were associated with poor muscle composition and worse physical function in studies of older adult humans that were published by our group. Interestingly, higher colonic levels of SCFAs are associated with a lower pH, an important finding because growth of Enterobacteriaceae, a bacterial family that contains genes involved in the production of IS, PCS, PS, and PAG, is limited in an acidic environment and following exposure to physiological levels of SCFAs. Taken together, these data suggest that interventions aimed at increasing bacterial SCFA production may be an important approach for improving muscle-related measures in older adults.

Soluble fiber fermentation by gut bacteria results in the formation of acetate, propionate, and butyrate, and fecal SCFAs proportionally increase, whereas circulating levels of IS and PCS are reduced in response to high-soluble fiber diets. As a proof of concept, fecal and circulating levels of SCFAs, muscle mass, and aerobic exercise capacity were increased in young mice that were fed a relatively higher soluble fiber diet, but few studies have attempted this approach in older adult humans. When considering that fecal levels of SCFAs decrease during aging, whereas plasma levels of IS, PCS, PS, and PAG increase, these data collectively suggest that a high-soluble fiber diet may be an important approach for improving muscle-related measures in older adults humans. To test this hypothesis, older adults will be randomized to consume a high- or low-soluble fiber diet for 12-weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Independently living older adults (> 65y)
  • Sedentary (Godin-Shepard Leisure Time Physical Activity Questionnaire score < 10)
  • Non-smoking
  • Not already consuming a high-fiber diet (> 22, 28 g/day for women, men)
  • Free of gastrointestinal disease (gastrointestinal cancer, inflammatory bowel disease, bariatric surgery, irritable bowel syndrome)
  • Fluent in English
  • Willing to attend three study visits (enrollment, baseline, and week-13)
  • Willing to consume an abundance of fruits, vegetables, nuts/seeds
  • Willing to consume an abundance of soluble fiber-rich foods (broccoli, brussels sprouts, flaxseeds sweetened with dates, lima beans, butternut squash, carrots, collard greens)
  • Willing to tolerate mild gastrointestinal discomfort (bloating, belly grumbling, flatulence). Note that all attempts will be made to replace foods that may trigger these issues.
  • Willing to not consume antibiotics during the 13-week study
  • Willing to not schedule a colonoscopy during the 13-week study

排除标准

  • Unwilling to visit the Tufts Human Nutrition Research Center on Aging (HNRCA) 3x/week to pick up the pre-prepared study diet
  • Unwilling to only consume the provided food (unsweetened tea and/or black coffee are allowed)
  • Food allergies related to foods that are included in the study
  • Chewing problems
  • Unwilling to wear a daily step counter (pedometer)
  • Unwilling to complete a daily questionnaire that will assess gastrointestinal comfort
  • Malnutrition (BMI < 18.5 kg/m2)
  • Use of supplemental probiotics or antibiotics, participation in an investigational drug evaluation, or a recent change in habitual medication use within the 1 month-period prior to the screening visit
  • > 5% weight loss or weight gain within the past 6-months
  • A recent history of alcohol abuse (within the past 5 years)
  • A history of any significant injury or surgery that currently affects physical functioning and ability to perform physical function testing
  • Treatment with immunosuppressive drugs
  • A prior diagnosis of organ failure (heart, liver, renal, respiratory)
  • Diabetes mellitus (type 1, or type 2 with insulin therapy)
  • Chronic kidney disease (eGFR ≤ 30 mL/min/1.73 m2)
  • Overt disease (cancer, dementia, cardiovascular disease)
  • Chronic use of anti-inflammatory medication (corticosteroids)
  • Already enrolled in another research study
  • Active infection, including Tuberculosis , HIV, malaria, hepatitis, shingles, Methicillin-Resistant Staphylococcus Aureus (MRSA), SARS-CoV-2
  • Any major illness or condition that may interfere with study outcomes at the discretion of the study physician
  • Won't remain in Boston for the 13-week study duration
  • Unwilling to complete a daily checklist aimed at quantifying the amount of food eaten on the study diet

结局指标

主要结局

Chair stand test

时间窗: Change from baseline when compared with the Week-13 visit

The number of chair stands that can be performed in 30 seconds will be determined at the baseline and week-13 study visits

Quantification of SCFAs in fecal samples

时间窗: Change from baseline when compared with the Week-13 visit

Fecal levels of bacterial metabolites, including acetate, propionate, and butyrate will be determined at the baseline and week-13 study visits

Quantification of whole-body lean mass with DXA

时间窗: Change from baseline when compared with the Week-13 visit

Measurement of whole-body lean mass will be determined at the baseline and week-13 study visits

Quantification of hand grip strength

时间窗: Change from baseline when compared with the Week-13 visit

Grip strength will be determined at the baseline and week-13 study visits

次要结局

  • Quantification of gut bacterial composition in fecal samples(Change from baseline when compared with the Week-13 visit)
  • Quantification of thigh muscle composition with computed tomography(Change from baseline when compared with the Week-13 visit)
  • 6-minute walk test(Change from baseline when compared with the Week-13 visit)
  • Quantification of gut bacterial metabolites in plasma(Change from baseline when compared with the Week-13 visit)
  • Quantification of pH in fecal samples(Change from baseline when compared with the Week-13 visit)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jennifer Lee

Principal Investigator

Tufts University

研究点 (2)

Loading locations...

相似试验